112 related articles for article (PubMed ID: 38678014)
1. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
2. Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy.
Lan M; Lu W; Zou T; Li L; Liu F; Cai T; Cai Y
Cell Mol Life Sci; 2021 Mar; 78(5):2105-2129. PubMed ID: 33386887
[TBL] [Abstract][Full Text] [Related]
3. A vascularized breast cancer spheroid platform for the ranked evaluation of tumor microenvironment-targeted drugs by light sheet fluorescence microscopy.
Ascheid D; Baumann M; Pinnecker J; Friedrich M; Szi-Marton D; Medved C; Bundalo M; Ortmann V; Öztürk A; Nandigama R; Hemmen K; Ergün S; Zernecke A; Hirth M; Heinze KG; Henke E
Nat Commun; 2024 Apr; 15(1):3599. PubMed ID: 38678014
[TBL] [Abstract][Full Text] [Related]
4. Assessing Advantages and Drawbacks of Rapidly Generated Ultra-Large 3D Breast Cancer Spheroids: Studies with Chemotherapeutics and Nanoparticles.
Holub AR; Huo A; Patel K; Thakore V; Chhibber P; Erogbogbo F
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575896
[TBL] [Abstract][Full Text] [Related]
5. 3D microengineered vascularized tumor spheroids for drug delivery and efficacy testing.
Ahn J; Kim DH; Koo DJ; Lim J; Park TE; Lee J; Ko J; Kim S; Kim M; Kang KS; Min DH; Kim SY; Kim Y; Jeon NL
Acta Biomater; 2023 Jul; 165():153-167. PubMed ID: 36243378
[TBL] [Abstract][Full Text] [Related]
6. 3D Bioprinted Vascularized Tumour for Drug Testing.
Han S; Kim S; Chen Z; Shin HK; Lee SY; Moon HE; Paek SH; Park S
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340319
[TBL] [Abstract][Full Text] [Related]
7. Vascularized Lung Cancer Model for Evaluating the Promoted Transport of Anticancer Drugs and Immune Cells in an Engineered Tumor Microenvironment.
Kim D; Hwang KS; Seo EU; Seo S; Lee BC; Choi N; Choi J; Kim HN
Adv Healthc Mater; 2022 Jun; 11(12):e2102581. PubMed ID: 35286780
[TBL] [Abstract][Full Text] [Related]
8. RNAi High-Throughput Screening of Single- and Multi-Cell-Type Tumor Spheroids: A Comprehensive Analysis in Two and Three Dimensions.
Fu J; Fernandez D; Ferrer M; Titus SA; Buehler E; Lal-Nag MA
SLAS Discov; 2017 Jun; 22(5):525-536. PubMed ID: 28277887
[TBL] [Abstract][Full Text] [Related]
9. Colorectal Cancer Organoid-Stroma Biobank Allows Subtype-Specific Assessment of Individualized Therapy Responses.
Farin HF; Mosa MH; Ndreshkjana B; Grebbin BM; Ritter B; Menche C; Kennel KB; Ziegler PK; Szabó L; Bollrath J; Rieder D; Michels BE; Kress A; Bozlar M; Darvishi T; Stier S; Kur IM; Bankov K; Kesselring R; Fichtner-Feigl S; Brüne B; Goetze TO; Al-Batran SE; Brandts CH; Bechstein WO; Wild PJ; Weigert A; Müller S; Knapp S; Trajanoski Z; Greten FR
Cancer Discov; 2023 Oct; 13(10):2192-2211. PubMed ID: 37489084
[TBL] [Abstract][Full Text] [Related]
10. Large-scale high-throughput 3D culture, imaging, and analysis of cell spheroids using microchip-enhanced light-sheet microscopy.
Zhu T; Nie J; Yu T; Zhu D; Huang Y; Chen Z; Gu Z; Tang J; Li D; Fei P
Biomed Opt Express; 2023 Apr; 14(4):1659-1669. PubMed ID: 37078040
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer and fibrosis: Targeting metabolic reprogramming and crosstalk of cancer-associated fibroblasts in the tumor microenvironment.
Li X; Zhou J; Wang X; Li C; Ma Z; Wan Q; Peng F
Front Immunol; 2023; 14():1152312. PubMed ID: 37033960
[TBL] [Abstract][Full Text] [Related]
12. Ranking Breast Cancer Drugs and Biomarkers Identification Using Machine Learning and Pharmacogenomics.
Mehmood A; Nawab S; Jin Y; Hassan H; Kaushik AC; Wei DQ
ACS Pharmacol Transl Sci; 2023 Mar; 6(3):399-409. PubMed ID: 36926455
[TBL] [Abstract][Full Text] [Related]
13. Image-based modeling of vascular organization to evaluate anti-angiogenic therapy.
Ascheid D; Baumann M; Funke C; Volz J; Pinnecker J; Friedrich M; Höhn M; Nandigama R; Ergün S; Nieswandt B; Heinze KG; Henke E
Biol Direct; 2023 Mar; 18(1):10. PubMed ID: 36922848
[TBL] [Abstract][Full Text] [Related]
14. Targeting galectin-driven regulatory circuits in cancer and fibrosis.
Mariño KV; Cagnoni AJ; Croci DO; Rabinovich GA
Nat Rev Drug Discov; 2023 Apr; 22(4):295-316. PubMed ID: 36759557
[TBL] [Abstract][Full Text] [Related]
15. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Yao D; Das P; San-Miguel J
J Clin Oncol; 2023 Jan; 41(3):568-578. PubMed ID: 35960908
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
